1. Netherlands Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
argenx SE

argenx SE

0QW0.IL
argenx SEGB flagInternational Order Book
865.60
EUR
+11.10
- -
54.15BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.24
0.6
0.48
0.82
1.78
0.68
2.03
0.91
9.74
7.55
21.45
36.59
67.76
84.24
Basic EPS, GAAP
-0.54
-1.66
-1.06
-1.19
-1.37
-2.12
-4.69
-13.4
-7.99
-13.05
-5.16
13.92
21.08
27.64
Free Cash Flow per Basic Share
-0.59
-0.87
-0.99
0.54
-1.8
-1.73
2.72
-8.89
-14.26
-17.78
-8.12
-2.52
9.36
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.91
3.88
2.58
3.31
12.86
17.12
27.6
35.19
49.05
50.79
69.22
90.49
118.34
134.59
Tangible Book Value per Share
1.91
3.88
2.58
3.31
12.86
17.12
26.55
31.67
45.73
47.64
67.11
87.5
113.94
130.34
Basic Weighted Avg Shares
16
8
16
19
25
36
39
45
51
54
57
60
61
62
Sales/Revenue/Turnover
4
5
7
15
44
25
78
41
497
411
1,226
2,190
4,153
5,228
Operating Margin (%)
-232.69
-286.02
-227.68
-145.56
-62.97
-381.01
-255.04
-1,165.21
-72.37
-176.24
-34.3
-0.81
25.39
30.56
Depreciation Expense
- -
- -
- -
- -
1
1
2
4
6
104
111
18
28
- -
Net Income, GAAP
-8
-13
-17
-22
-34
-76
-181
-608
-408
-710
-295
833
1,292
1,715
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.78
Profit Margin (%)
-229.03
-274.6
-223.4
-145.27
-77.1
-310.22
-230.95
-1,475.29
-82.1
-172.76
-24.06
38.03
31.11
32.81
Working Capital
29
60
39
73
411
609
1,363
1,729
2,242
2,472
3,701
4,213
5,579
6,493
LT Debt
- -
- -
- -
- -
- -
- -
5
6
8
9
15
33
36
36
Total Equity
30
61
41
67
414
616
1,180
1,674
2,534
2,814
4,098
5,498
7,323
8,417
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
21.39
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
23.54
Return on Common Equity (%)
-36.32
-27.6
-32.94
-41.86
-14.02
-14.81
-20.18
-42.63
-19.4
-26.54
-8.54
17.36
20.15
23.64

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
11
- -
11
LT Borrowings
- -
- -
- -
LT Finance Leases
36
- -
36
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
62
62
63
Market Capitalization
44,265
38,442
50,868

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,899
- -
8,068
Cash, Cash Equivalents & STI
4,440
- -
5,184
Accounts Receivable, Net
1,490
- -
1,832
Inventories
474
- -
371
Total Current Liabilities
1,320
- -
1,575
Payables & Accruals
695
- -
925
ST Debt
11
- -
11
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
94.21%
35.08%
33.19%
Free Cash Flow
-189.63%
-97.19%
-479.69%
Net Income, GAAP
23.92%
-68.95%
55.1%
Sales/Revenue/Turnover
187.2%
291.02%
89.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
401
478
573
738
2,190
2025
790
948
1,127
1,288
4,153
2026
1,298
1,515
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.04
- -
1.52
- -
13.92
2025
2.77
- -
- -
- -
21.08
2026
5.9
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Karen Massey
Full Time Employees
1,863
Sector
Healthcare
Industry
Biotechnology
Address
Laarderhoogtweg 25 Amsterdam NH Netherlands 1101EB
IPO Date
Nov 30, 2015
Website
argenx.com
Similar Companies
Roivant Sciences Ltd. (ROIV)
Laekna, Inc. (2105.HK)
Inhibrx Biosciences, Inc. Common Stock When Issued (INXBV)
Catalyst Pharmaceuticals, Inc. (CPRX)
IntelGenx Technologies Corp. (IGXT)
TuHURA Biosciences, Inc. (HURA)
Business
argenx SE is a biotechnology company that discovers and develops antibody-based therapeutics for cancer and autoimmune diseases, focusing on engineered antibodies and antibody-drug conjugates that modulate immune responses and target disease pathways. Its core products and services span the discovery, development, manufacturing, and commercialization of therapeutic antibodies and related modalities, including antibody formats, bispecific antibodies, and novel immune-oncology programs; collaboration and licensing arrangements with pharmaceutical partners; early and late-stage clinical development, including Phase I-III trials; biomarker and translational science support; GMP-compliant manufacturing and process development for clinical and commercial supply; and regulatory submissions and commercialization activities for approved therapies. Latest major company changes include ongoing strategic collaborations and licensing deals with global biopharma entities to advance pipeline programs; acquisitions or asset acquisitions within the immunology and oncology space to expand therapeutic portfolios; the advancement of key clinical programs through pivotal trial readouts or regulatory submissions; expansion of manufacturing capabilities and capacity through investments in process development and facility upgrades; and corporate governance updates or reorganizations aligned with growth and global commercialization strategies. Additional context: - Industry and segments: biotechnology; immunology, oncology, autoimmunity; research and development, clinical development, regulatory affairs, manufacturing, and commercialization - Target markets: patients with cancer and autoimmune disorders; research and development partners; contract manufacturing and collaboration agreements - Geographic operations: headquarters in Europe with global clinical development activities and regional commercialization; operations and collaborations across North America, Europe, and Asia - Founding year and headquarters: founded in 20XX (specific year not stated here) with headquarters in Europe - Subsidiaries/parent: operates as a standalone publicly traded company with potential subsidiaries or affiliates supporting research, development, manufacturing, and regional commercial activities